Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | NPC1 | O15118 | 2/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | GMNN | O75496 | 1/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | HTR1A | P08908 | 1/20 | 0.73 |
| ▸ | THRB | P10828 | 1/20 | 0.73 |
| ▸ | PIM1 | P11309 | 1/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.73 |
| ▸ | MAOA | P21397 | 1/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.73 |
| ▸ | HTR2A | P28223 | 1/20 | 0.73 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.73 |
| ▸ | CCKBR | P32239 | 1/20 | 0.73 |
| ▸ | MC4R | P32245 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | THPO | P40225 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19376825 | 0.87 | RAB9A (0.59) | RAB9ASMN1; SMN2NPC1LMNAGMNN | |
| SCHEMBL19376876 | 0.87 | RAF1 (0.61) | RAB9ASMN1; SMN2NPC1LMNAGMNN | |
| SCHEMBL26657307 | 0.86 | RAB9A (0.58) | RAB9ASMN1; SMN2NPC1LMNAGMNN | |
| Leflunomide SCHEMBL1243495 | 0.84 | RAB9A (1.00) | RAB9ASMN1; SMN2NPC1LMNAGMNN | |
| Leflunomide SCHEMBL5057 | 0.84 | RAB9A (1.00) | RAB9ASMN1; SMN2NPC1LMNAGMNN | |
| SCHEMBL11666432 | 0.83 | SMN1; SMN2 (0.53) | RAB9ASMN1; SMN2NPC1LMNAGMNN | |
| Leflunomide SCHEMBL29271960 | 0.81 | RAB9A (0.92) | RAB9ASMN1; SMN2NPC1LMNAGMNN | |
| SCHEMBL24047118 | 0.81 | SMN1; SMN2 (0.48) | RAB9ASMN1; SMN2NPC1LMNAGMNN | |
| SCHEMBL9182578 | 0.80 | RAB9A (0.69) | RAB9ASMN1; SMN2NPC1LMNAGMNN | |
| SCHEMBL3885508 | 0.80 | RAB9A (0.55) | RAB9ASMN1; SMN2NPC1LMNAGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691890-B2 | Anti-viral uses of leflunomide products | Williams, James W. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-1169036-B1 | ANTI-VIRAL USES OF LEFLUNOMIDE PRODUCTS | WILLIAMS JAMES W (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1155004-B1 | METHOD CRYSTALLISING N-(4-TRIFLUOROMETHYLPHENYL)-5-METHYL-ISOXAZOLE-4-CARBOXAMIDE | AVENTIS PHARMA GMBH (DE) | 2004-01-14 | — | — | EP | disclosed |
| US-20030114507-A1 | Anti-viral uses of leflunomide products | WILLIAMS, JAMES, DR. | 2003-06-19 | — | — | US | disclosed |
| EP-1169036-A2 | ANTI-VIRAL USES OF LEFLUNOMIDE PRODUCTS | Ohio State Research Foundation (US) | 2002-01-09 | — | — | EP | disclosed |
| EP-1155004-A1 | METHOD CRYSTALLISING N-(4-TRIFLUOROMETHYLPHENYL)-5-METHYL-ISOXAZOLE-4-CARBOXAMIDE | Aventis Pharma Deutschland GmbH (DE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050411-A1 | METHOD CRYSTALLISING N-(4-TRIFLUOROMETHYLPHENYL)-5-METHYL-ISOXAZOLE-4-CARBOXAMIDE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-08-31 | — | — | WO | disclosed |
| WO-1999045908-A2 | ANTI-VIRAL USES OF LEFLUNOMIDE PRODUCTS | OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1999-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114507-A1 | Anti-viral uses of leflunomide products | UMPS, UPP1, PNP | RAB9A 2556/4885SMN1; SMN2 1749/4885NPC1 1905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.